Hydralazine as a Demethylating Agent in Rectal Cancer
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Clinically feasible dose of Hydralazine for ~ 3 months, by virtue of its demethylating
effect, will:
1. Result in re-expression of epigenetically silenced TSGs in rectal cancer specimens.
2. Decrease the global methylation in primary cancer cells compared to pre-treatment